BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...She was VP, managed markets and trade, at Assertio Therapeutics Inc. (NASDAQ:ASRT). Cancer radiotherapy company Theragnostics Ltd....
BioCentury | Jan 28, 2019
Company News

Management tracks: Ironwood reveals board for new companies

...position. He was interim VP of oncology clinical development at Pfizer Inc. (NYSE:PFE). Radiopharmaceuticals company Theragnostics Ltd....
BioCentury | Oct 20, 2017
Clinical News

DSMB backs Athenex's Phase III breast cancer trial of Oraxol

...Inc. ATP-binding cassette sub-family B member 1 (ABCB1) (MDR1) (PGP) (CD243) P glycoprotein Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) 68Ga-THP-PSMA Theragnostics Ltd....
BioCentury | Oct 19, 2017
Clinical News

Theragnostics reports Phase I data for prostate cancer imaging agent

...SOC) imaging agent in treatment-naïve patients scheduled for prostatectomy and in patients with metastatic disease. Theragnostics...
...The Journal of Nuclear Medicine . 68Ga-THP-PSMA comprises gallium linked by tris(hydroxypyridinone) (THP) to PSMA. Theragnostics Ltd....
...Safety and biodistribution Status: Phase I data Milestone: NA Jaime De Leon Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) 68Ga-THP-PSMA Theragnostics Ltd....
Items per page:
1 - 4 of 4
BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...She was VP, managed markets and trade, at Assertio Therapeutics Inc. (NASDAQ:ASRT). Cancer radiotherapy company Theragnostics Ltd....
BioCentury | Jan 28, 2019
Company News

Management tracks: Ironwood reveals board for new companies

...position. He was interim VP of oncology clinical development at Pfizer Inc. (NYSE:PFE). Radiopharmaceuticals company Theragnostics Ltd....
BioCentury | Oct 20, 2017
Clinical News

DSMB backs Athenex's Phase III breast cancer trial of Oraxol

...Inc. ATP-binding cassette sub-family B member 1 (ABCB1) (MDR1) (PGP) (CD243) P glycoprotein Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) 68Ga-THP-PSMA Theragnostics Ltd....
BioCentury | Oct 19, 2017
Clinical News

Theragnostics reports Phase I data for prostate cancer imaging agent

...SOC) imaging agent in treatment-naïve patients scheduled for prostatectomy and in patients with metastatic disease. Theragnostics...
...The Journal of Nuclear Medicine . 68Ga-THP-PSMA comprises gallium linked by tris(hydroxypyridinone) (THP) to PSMA. Theragnostics Ltd....
...Safety and biodistribution Status: Phase I data Milestone: NA Jaime De Leon Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) 68Ga-THP-PSMA Theragnostics Ltd....
Items per page:
1 - 4 of 4